In Brief: Nastech Nascobal
Executive Summary
Nastech Nascobal: Schwarz Pharma to market in the U.S. the intranasal B12 deficiency therapy Nascobal (cyanocobalamin). Schwarz also has the right to acquire exclusive European and Asian marketing rights, with Nastech retaining global manufacturing rights. Schwarz will pay Nastech annual royalties (between 20%-26%) on U.S. net sales. Nascobal is expected to be launched by January 1998. FDA approved the drug on Nov. 5 ("The Pink Sheet" Nov. 25, 1996, T&G-7)...